מעבר מחלקות סיכום אקראי: בדיקת דגמי חוסן-יעד תרופתי תחת שינויי התפלגות כימי וביולוגי

תקציר מקורי באנגליתarXiv:2610.03456v1 Announce Type: new Abstract: Drug-target affinity (DTA) prediction is widely used to prioritize candidate compounds before costly experimental screening. DTA models are often compared under a single data split, even though deployment may require extrapolation to new chemical series, new protein targets, or both. We ask whether the distribution shift used for evaluation changes which architecture appears best. We curate 718,800 unique drug-protein pairs from the ChEMBL and BindingDB datasets. We compare a Morgan-fingerprint + protein-CNN baseline with 12 controlled architectures that combine four drug representations with three ESM-2 interaction modes. Mean validation RMSE increases from 0.950 and 0.945 under scaffold and fingerprint-cluster OOD to 1.299 and 1.321 under p